Risk of hospitalization for stroke associated with antipsychotic use in the elderly: A self-controlled case series

Drugs and Aging

Volumn 27, Issue 11, 2010, Pages 885-893

  Pratt, Nicole L ^a   Roughead, Elizabeth E ^b   Ramsay, Emmae ^a   Salter, Amy ^a   Ryan, Philip ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Antipsychotics, therapeutic use; Elderly; Stroke

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TRIFLUOPERAZINE;

ADULT; AGED; AGING; ARTICLE; AUSTRALIA; CEREBROVASCULAR ACCIDENT; DELIRIUM; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CASE-CONTROL STUDIES; DEMENTIA; HOSPITALIZATION; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RISK ADJUSTMENT; RISK ASSESSMENT; RISK FACTORS; STROKE; VETERANS;

EID: 77958532593     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11584490-000000000-00000     Document Type: Article

References (37)

1. Australian Government, Department of Health and Ageing. Australian statistics on medicines [online]. Available from URL: http://www.health.gov.au/ internet/main/publishing.nsf/Content/pbs-pubs-asm2007 [Accessed 2010 Sep 2]
2. Ballard C, Fossey J, Sharp S. Antipsychotics in patients with Alzheimer's disease: what is their clinical value? Nat Clin Pract Neurol 2007; 3: 248-9
3. De Deyn PP, Katz IR, Brodaty H, et al. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg 2005; 107: 497-508
4. Katz I, de Deyn PP, Mintzer J, et al. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry 2007; 22: 475-84
5. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14: 191-210
6. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355: 1525-38
7. How safe are antipsychotics in dementia? Drug Ther Bull 2007; 45: 81-5
8. Australian Government, Department of Health and Ageing. Schedule of pharmaceutical benefits: PBS for health professionals [online]. Available from URL: http://www.pbs.gov.au/html/healthpro/home [Accessed 2010 Sep]
9. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; (1): CD003476
10. Herrmann N, Lanctot KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005; 19: 91-103
11. Kolanowski A, Fick D, Waller JL, et al. Outcomes of antipsychotic drug use in community-dwelling elders with dementia. Arch Psychiatr Nurs 2006; 20: 217-25
12. Barnett MJ, Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol 2007; 27: 595-601
13. Sacchetti E, Trifiro G, Caputi A, et al. Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. J Psychopharmacol 2008; 22: 39-46
14. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008; 337: a1227
15. Sacchetti E, Turrina C, Cesana B, et al. Timing of stroke in elderly people exposed to typical and atypical antipsy-chotics: a replication cohort study after the paper of Kleijer et al. J Psychopharmacol 2009 Jul; 24 (7): 1131-2
16. Kleijer BC, van Marum RJ, Egberts AC, et al. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol 2009 Nov; 23 (8): 909-14
17. Herrmann N, Mamdani M, Lanctot KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161: 1113-5
18. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330: 445
19. Finkel S, Kozma C, Long S, et al. Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics. Int Psychogeriatr 2005; 17: 617-29
20. Wang PS, Schneeweiss S, Setoguchi S, et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol 2007; 27: 707-10
21. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 2005; 353: 2335-41
22. Hallas J. Pharmacoepidemiology: current opportunities and challenges. Norweg J Epidemiol 2001; 11: 7-12
23. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007; 176: 627-32
24. Hollis J, Grayson D, Forrester L, et al. Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatr Psychiatry 2007; 15: 932-41
25. Whitaker HJ, Farrington CP, Spiessens B, et al. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006; 25: 1768-97
26. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical therapeutic chemical code classification index with defined daily doses [online]. Available from URL: http://www.whocc.no/atcddd/ [Accessed 2010 Sep 2010]
27. The international statistical classification of diseases and related health problems, 10th revision, Australian modification (ICD-10-AM). 6th ed. Sydney (NSW): National Centre for Classification in Health, 2005
28. Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res 2009 Feb; 18 (1): 7-26
29. Hubbard R, Lewis S, West J, et al. Bupropion and the risk of sudden death: a self-controlled case-series analysis using the Health Improvement Network. Thorax 2005; 60: 848-50
30. McManus J, Pathansali R, Stewart R, et al. Delirium poststroke. Age Ageing 2007; 36: 613-8
31. Oldenbeuving AW, de Kort PL, Jansen BP, et al. Delirium in acute stroke: a review. Int J Stroke 2007; 2: 270-5
32. eTG complete. Melbourne (VIC): Therapeutic Guidelines Ltd, 2010
33. Normand SL, Sykora K, Li P, et al. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 2005; 330: 1021-3
34. Liperoti R, Onder G, Lapane KL, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry 2007; 68: 929-34
35. Hugenholtz GW, Heerdink ER, van Staa TP, et al. Risk of hip/femur fractures in patients using antipsychotics. Bone 2005; 37: 864-70
36. Pouwels S, van Staa TP, Egberts AC, et al. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 2009 Sep; 20 (9): 1499-506
37. Farrington CP, Whitaker HJ. Semiparametric analysis of case series data. Appl Stat 2006; 55: 553-94